Claims for Patent: 6,750,255

Summary for Patent: 6,750,255

Title:	Calcium receptor-active compounds
Abstract:	A novel calcium receptor active compound having the formula is provided: wherein: Ar.sub.1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are, for example, hydrogen or alkyl; Ar.sub.2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.
Inventor(s):	Sakai; Teruyuki (Gunma, JP), Takami; Atsuya (Gunma, JP), Nagao; Rika (Gunma, JP)
Assignee:	NPS Pharmaceuticals, Inc. (Salt Lake City, UT) Kirin Beer Kabushiki (Tokyo, JP)
Application Number:	10/053,133
Patent Claims:	1. A compound having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is optionally substituted naphthyl, or phenyl substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; or a pharmaceutically acceptable salt or hydrate of said compound. 2. The compound, salt or hydrate of claim 1 wherein: R.sup.3, R.sup.4, R.sup.5 and R.sup.8 are independently H; R.sup.6 and R.sup.7 are H or unsubstituted lower alkyl; R.sup.9 is unsubstituted lower alkyl; and q is an integer of from 0 to 7, inclusive. 3. The compound, salt or hydrate of claim 2 wherein: Ar.sub.1 is phenyl optionally substituted with one or more groups independently selected from the group consisting of halogen, and trihalomethyl; Ar.sub.2 is phenyl optionally substituted with one or more methoxy groups; R.sup.8 is H; and R.sup.9 is methyl. 4. The compound, salt or hydrate of claim 3 wherein X is O. 5. The compound, salt or hydrate of claim 3 wherein X is S. 6. A compound selected from the group consisting of: ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. 7. A compound selected from the group consisting of: ##STR2## or a pharmaceutically acceptable salt or hydrate thereof. 8. The compound, salt or hydrate of claim 2 wherein: Ar.sub.1 is benzothiazole, benzoxazole, or phenyl substituted with an unsubstituted fused phenyl ring; Ar.sub.2 is phenyl optionally substituted with one or more methoxy groups; X is S; R.sup.6 is H; and R.sup.9 is methyl. 9. A compound selected from the group consisting of: ##STR3## or a pharmaceutically acceptable salt or hydrate thereof. 10. A compound selected from the group consisting of: ##STR4## or a pharmaceutically acceptable salt or hydrate thereof. 11. The compound, salt or hydrate of claim 1, wherein said compound is the R enantiomer. 12. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is optionally substituted naphthyl, or phenyl substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 13. A method of treating a patient comprising administering to said patient a therapeutically effective amount of one or more of compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is optionally substituted naphthyl, or phenyl substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 14. The method of claim 13 wherein said patient is suffering from a disease or disorder characterized by either or both of (1) abnormal calcium homeostasis and, (2) an abnormal amount of an intracellular or extracellular messenger whose production can be affected by calcium receptor activity. 15. A method for modulating the PTH level in a patient comprising administering to said patient an effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 16. The method of claim 15 wherein said effective amount of said compound reduces said PTH level in a patient. 17. The method of claim 16 wherein said patient has an abnormally high PTH level and effective amount of said compound reduces said PTH level in said patient to a degree sufficient to cause a decrease in plasma Ca.sup.2+. 18. The method of claim 15, wherein administering said compound to said patient results in a PTH level in said patient equal to a level present in a normal individual. 19. A method for modulating parathyroid hormone secretion in a patient comprising administering to said patient an effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 20. The method of claim 19 wherein said effective amount of said compound reduces said parathyroid hormone secretion in said patient. 21. The method of claim 19 wherein said patient has an abnormally high parathyroid secretion and said therapeutically effective amount of said compound reduces said parathyroid hormone secretion in said patient to a degree sufficient to cause a decrease on plasma Ca.sup.2+. 22. A method for modulating one or more Ca.sup.2+ receptors activities in a cell comprising administration to said cell one or more compounds, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 23. The method of claim 22 wherein said cell is a parathyroid cell, a juxtaglomerular kidney cell, a proximal tubule kidney cell, a parafollicular thyroid cell, a bone osteoclast, a keratinocyte or a placental trophoblast. 24. A method for treating or preventing a disorder selected from the group consisting of hyperparathyroidism, renal osteodystrophy, hypercalcemia malignancy, osteoporosis, Paget's disease and hypertension comprising administering to a patient suffering from said disorder a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive. 25. The method of claim 24 wherein said hyperparathyroidism is primary hyperparathyroidism. 26. The method of claim 24 wherein said hyperparathyroidism is secondary hyperparathyroidism. 27. A pharmaceutical composition for treatment of primary and secondary hyperparathyroidism comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; wherein the composition is useful for the treatment of primary and secondary hyperparathyroidism. 28. A pharmaceutical composition for treatment of renal osteodystrophy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; wherein the composition is useful in the treatment of renal osteodystrophy. 29. A pharmaceutical composition for treatment of hypercalcemia comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; wherein the composition is useful in the treatment of hypercalcemia. 30. A pharmaceutical composition for treatment of hypercalcemia malignancy comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; wherein the composition is useful in the treatment of hypercalcemia malignancy. 31. A pharmaceutical composition for treatment of osteoporosis comprising a compound, or a pharmaceutically acceptable salt or hydrate thereof, having the formula: wherein: Ar.sub.1 is phenyl, benzothiazole, or benzoxazole, wherein if Ar.sub.1 is phenyl, Ar.sub.1 is optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens, phenyl, nitro, a substituted or unsubstituted phenyl ring fused to Ar.sub.1 through two adjacent substituents, and a substituted or unsubstituted heteroaryl ring fused to Ar.sub.1 through two adjacent substituents, and; Ar.sub.2 is phenyl optionally substituted with one or more moieties independently selected from the group consisting of halogen, unsubstituted alkyl, lower alkyl substituted with one or more halogens, lower alkoxy optionally substituted with one or more halogens; and an unsubstituted phenyl ring fused to Ar.sub.2 through two adjacent substituents; X is selected from the group consisting of O or S; R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are independently hydrogen or alkyl; q is an integer of from 0 to 14, inclusive; wherein the composition is useful in the treatment of osteoporosis.

Details for Patent 6,750,255

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2016-07-08